News Hub | News Direct

How IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The Past

Benzinga

By Ted Stavetski, Benzinga IN8bio Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company tackling one of society’s most pressing issues: cancer. Specifically, the company is focused on using the immune system to eliminate residual tumors, and currently has two clinical programs focused on leukemia and on glioblastoma, the deadliest type of brain cancer. IN8bio is pioneering a new approach using the immune system to tackle the deficiencies that plague most current cancer treatments. Alpha-beta T cell-based chimeric antigen receptor, or CAR-T therapies have shown remarkable results against some leukemias and myelomas. However, many of these CAR-T treatments have faced challenges against more difficult-to-treat leukemias, such as acute myeloid leukemia (AML) and solid tumor cancers. These cancers can be highly heterogenous, making them difficult to kill since they are often intertwined in healthy tissues, leading to unintentional toxicities and adverse events. In some cases, patients have even died. Fortunately, IN8bio may have found the solution to this problem. What Is “Cancer Zero?” IN8bio set out on a mission that it calls “Cancer Zero”, which co-founder and CEO William Ho describes as “the goal of pursuing the safe eradication of all tumor cells in patients fighting cancer.” In other words, the company aims to eliminate all cancer cells without destroying healthy cells. To achieve this, the company has developed advanced technologies using a specific subset of immune cells, or lymphocytes called gamma-delta T cells, in its DeltEx platform. Gamma-delta T cells are white blood cells whose job in the body is to be a first-responder and to determine safe and not-safe. They kill invading or dangerous cells and can call in reinforcements by recruiting and activating other immune cells. It was IN8bio’s co-founder, Dr. Lawrence Lamb, a clinical immunologist on a cancer ward treating patients with aggressive leukemias in the 1990s, who made the first observation that gamma-delta T cells are linked to greater survival in cancer patients. He spent the next 25 years figuring out how to expand, genetically engineer and manufacture gamma-delta T cells at scale and into a cancer therapy. In 2016, IN8bio was launched to take these gamma-delta T cell technologies into the clinic and today, Dr. Lamb is IN8bio’s Chief Scientific Officer. He leads a team of scientists and researchers dedicated to achieving the company’s mission of Cancer Zero. IN8bio’s DeltEx platform uses gamma-delta T cells that it believes are potentially safer and more effective at killing cancer cells than other therapies currently in development. The company has the capability to utilize autologous (from the patient), allogeneic (from a donor or “off-the-shelf”) and induced pluripotent stem cell (iPSC)-derived gamma-delta T cells. These cells can be expanded, activated and genetically engineered outside of the body to increase their numbers and to enhance their hunting and killing abilities. In one platform unique to IN8bio, its drug resistant immunotherapy (DRI) technology enhances gamma-delta T cells by genetically engineering them to be chemotherapy resistant. Chemotherapies have been a mainstay of front-line cancer therapy since World War II. While effective at shrinking a tumor and prolonging survival, they also kill white blood cells. As a result, microscopic residual tumors that are resistant to therapy often remain and result in relapse because of the weakened immune system. IN8bio’s DRI approach allows the simultaneous combination of chemotherapy with an immune therapy that may create synergies that allow the DRI gamma-delta T cells to recognize and eliminate the residual tumor cells while leaving healthy tissues alone. By targeting compartments of residual tumor cells, IN8bio’s DRI approach may achieve deeper tumor responses that can prolong survival. The company has already protected the DRI technology behind this process with issued patents around the world. IN8bio: Drugs In Clinical Development IN8bio has three therapies that are in varying stages of clinical development: INB-400: A phase 2 multi-center clinical trial for the treatment of newly diagnosed glioblastoma, or GBM ( NCT05664243 ). This trial has recently initiated enrollment at leading brain tumor centers across the United States following clearance of a company-sponsored investigational new drug application, or IND, by the U.S. Food and Drug Administration, or FDA. This program received Orphan Drug Designation (ODD) from the FDA in the spring of 2023 for targeting a significant unmet medical need, which offers potential incentives such as 7-year market exclusivity. INB-200: A phase 1 clinical trial at the University of Alabama at Birmingham using autologous, genetically modified DRI gamma-delta T cells for the treatment for newly diagnosed glioblastoma (UAB - NCT04165941 ). This program was one of only four central nervous system (CNS) cancer programs to have received an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest world-wide yearly gathering of cancer clinicians and researchers. At that time, the company released initial phase 1 data showing that 100% of treated patients have exceeded expected median progression-free survival. An additional clinical update is expected in November 2023 at the Society for Neuro-Oncology Annual Meeting (SNO), and long-term follow-up data is expected to be presented at medical meetings in the first half of 2024. INB-100: A phase 1 trial for the treatment of patients with high-risk leukemias undergoing haploidentical stem cell transplantation, or HSCT ( NCT03533816 ). The company presented a clinical update at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting in April 2023 that demonstrated 100% of evaluable patients (n=7) treated with INB-100 remained alive, progression-free and in durable complete remission (CR) as of April 21, 2023. Patients included high-risk AML patients and a patient with acute lymphoblastic leukemia (ALL) who had failed four prior lines of therapy, including CAR-T. All evaluable patients remained alive as of the last assessment and one patient had survived for three years. IN8bio has completed primary enrollment of the phase 1 clinical trial, with updated results expected at the American Society of Hematology (ASH) Annual meeting in December 2023. Topline long term follow ups are expected in 2024. To further its research, IN8bio recently opened a new 10,000-square-foot research & development (R&D) facility in Birmingham, Alabama. This state-of-the-art facility not only bolsters the company’s ability to advance its groundbreaking pipeline of gamma-delta T cell therapies, but also further taps into the advanced cancer research at the UAB, and other prominent institutes. Additionally, the company holds a total of 19 granted U.S. and international patents with many more still pending approval. This will help IN8bio protect its innovative new therapies from competitors as they proceed through clinical trials towards future commercialization. Cancer Immunotherapy Market IN8bio is tackling a large market. Grand View Research estimates that the global cancer immunotherapy market was worth approximately $115 billion in 2022 and is expected to grow at a compound annual growth rate of 8.7% from 2023 to 2030. Diving deeper, the American Cancer Society estimates that there will be 59,610 new cases of leukemia (and 23,710 deaths) in 2023, and the National Brain Tumor Society estimates that there were 13,400 new cases of glioblastoma in 2022. Despite being a lesser-known disease, awareness of glioblastoma is growing quickly. This is mainly due to the unfortunate, high-profile deaths of the President’s son, Beau Biden, and former U.S. Senator John McCain. One Step Closer Towards Cancer Zero IN8bio’s portfolio of cell therapies has the potential to offer a better treatment option for patients suffering from difficult to treat solid and liquid tumors such as AML and glioblastoma. The company’s primary advantage is its patent-protected platform gamma-delta T cell technologies, which it believes may allow it to better target cancer cells, getting deeper responses without hurting the patient’s healthy cells. The biotechnology company has had its foot on the gas pedal in recent years, boasting the following achievements: Two programs in phase 1, and enrollment has been initiated in its corporate-sponsored phase 2 trial at multiple sites across the U.S. A portfolio of preclinical programs in development including: iPSC derived gamma-delta T cells platform. iPSCs represent a significant step toward next generation approaches of cellular manufacturing for true allogeneic and potentially ‘off-the-shelf’ cellular therapies. INB-300, which focuses on addressing various solid and liquid tumors using a dedicated gamma-delta non-signaling CAR-T, or nsCAR, construct. These nsCAR constructs are designed specifically for the biology of gamma-delta T cells and allow IN8bio to potentially target tumor tissues while leaving healthy tissue alone. This could potentially create safer and more potent therapies. 19 granted patents for its technology. A brand new state-of-the-art R&D facility. $17 million in cash on hand, as of June 30, 2023, to help fund its operations and drug development. While the company is currently unprofitable – posting a net loss of $7.7 million for the three months ended June 30, 2023 – this is largely expected for biotechnology companies in the clinical development stage as they work to develop new drugs. However, IN8bio’s approach to business appears to be quite different in the biotechnology industry. The company reports it has been able to advance its clinical and preclinical programs by being extremely efficient with the capital raised, searching for innovative ways to advance their preclinical and clinical programs. Whereas IN8bio has successfully advanced multiple programs into phase 1 and 2 clinical trials while only having spent $76.5 million through 2Q23, a number of competing cell therapy companies have spent far more while showing similar, or less progress. Co-founder and CEO, William Ho has over 22 years of combined experience managing biotechnology companies, healthcare finance and investing, while co-founder and CSO, Lawrence Lamb has been in cellular therapy for three decades. They and the rest of the management team have the experience and know-how to effectively execute, manufacture, develop and advance the company’s growing portfolio of cancer therapies. With any luck, IN8bio will be able to achieve their mission of Cancer Zero, making cancer a thing of the past. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 06, 2023 09:00 AM Eastern Standard Time

Where Is Your Doctor Investing? Chances Are It Could Be DLP Capital – A Deep Dive Into The Returns Offered By The Firm’s Housing-Focused Funds

Benzinga

By Austin DeNoce, Benzinga Physicians, after years of intensive training and practice, are known for their rigorous and methodical approach when making decisions that impact their patients' health. This same attention to detail can often extend to their financial investments, and many are curious about where successful doctors invest their money. Treating patients, like investing, requires intelligence and patience. Among the myriad of investment choices available, DLP Capital emerges as an interesting choice due to its comparable ethos reflected in its broader vision of positively impacting society, and doctors seem to have taken notice – the company reports doctors have invested over $260 million in DLP Capital’s housing-focused funds. A Glimpse Into DLP Capital's Portfolio Since it was founded in 2006, DLP Capital has solidified its position in the investment landscape, earning a spot on the Inc. 5000 Fastest-Growing Companies list and retaining it for 11 consecutive years. The firm manages assets valued at over $5 billion, drawing support from a diverse pool of more than 2,600 investors. Owning and overseeing over 18,000 housing units, several of their funds have met or even surpassed their targeted returns. Through their varied endeavors, DLP Capital claims to have positively impacted more than 838,000 lives. Historical Returns: A Snapshot DLP Lending Fund: With a target annual return of 9-10%, this fund managed a 12.71% annual return as of September 30, 2023. As a private REIT emphasizing rental housing in high ownership-cost areas, it offers investors liquidity, a rigorous borrower vetting process and a 90-day redemption period without long-term constraints. Prioritizing investor returns, all preferred payouts are dispensed before any management fees, and invested capital retains a top-tier position, ensuring payment precedence over common equity participants. DLP Building Communities Fund: With an ambitious target of 11-13%, this fund achieved an annual return of 12.81% by the end of 2022. Designed as an evergreen private real estate fund, it focuses on developing new rental communities for attainable housing while providing a measure of protection against stock market volatility, consistent asset valuation for growth and flexible redemption options. All returns are prioritized to investors before any management fee is levied, ensuring their capital retains a preferred, high-priority position in all deals. DLP Preferred Credit Fund: This fund achieved a return of 10.52% in Q2 for 2023 on its 10-11% annual target, emphasizing insulation against rising interest rates and ensuring liquidity. By rigorously vetting borrowers and prioritizing loans to seasoned real estate sponsors, the fund ensures investors enjoy a preferred payment position and monthly returns before management fees, aligning the interests of DLP with its investors. Focusing on debt and preferred credit investments in the Sun Belt, its intent is to make a dent in America's affordable housing crisis, ensuring that rentals are attainable for working families. DLP Housing Fund: Perhaps the most eye-catching of the lot, DLP reports this fund saw an annual return of 27.04% by September 30, 2023, much higher than its annual target of 10-11%. By investing equity in multifamily rental communities (including manufactured housing and RV), the fund emphasizes both renter affordability and investor returns. The fund operates as an open-ended, private real estate venture focusing on long-term assets to yield enhanced returns. Investors not only benefit from tax advantages like depreciation offsets and 1031 tax-deferred exchanges, but they also enjoy flexible annual redemptions and a preferred position, guaranteeing payment priority over common equity investors. With returns like this, DLP may seem like a natural choice for many, but doctors are being attracted to DLP Capital for multiple reasons. The Attraction Of Passive Income One of the primary draws for busy professionals – such as those in the medical field – is the concept of passive income. They can enjoy the fruits of their investments without the daily demands of active engagement. DLP Capital's offerings, especially with its history of consistent returns, specifically aim to satisfy this demand for passive income – and doctors seem to find them particularly appealing. Impact Investing: Partnering With Doctors To Do Good Professionals like doctors frequently align their investment choices with societal benefits. Given the intrinsic desire among many in the medical profession to contribute positively to society, there's potential interest in DLP Capital, primarily due to its initiatives in affordable housing. Specifically, the DLP Housing Fund focuses on rental housing aimed at those with incomes near the area median. Likewise, the DLP Preferred Credit Fund and the DLP Building Communities Fund incorporate rental affordability into their strategies. Consequently, these funds combine financial objectives with addressing a relevant societal challenge. Exceeding Expectations DLP Capital has maintained a consistent investment record. Since its founding in 2006, there have been no reported capital losses for investors. Such reliable performance, alongside the size of potential returns, are important considerations for those evaluating investment options. Some of DLP Capital's funds have also achieved returns beyond their initial targets, reflecting reasonable success for some of its investment strategies. At the very least, their performance suggests a capacity to meet and occasionally exceed market expectations, though past performance is not a guarantee of future performance. Don Wenner, the CEO of DLP Capital, has played a significant role in the firm's direction. With over 16,000 real estate transactions amounting to more than $4 billion since 2006, his experience is extensive. Leveraging his experience, DLP's overarching mission includes both profit generation and broader goals to positively influence millions of lives. DLP Capital's Prognosis DLP Capital has positioned itself within the investment space by emphasizing passive income, societal impact and consistent returns – and successful professionals like doctors seem to be paying attention, with over a quarter of a billion invested by the medical community. The firm offers a comprehensive approach that integrates passive revenue streams, initiatives in affordable housing and a track record that reflects its strategy and performance over time. All returns aside, DLP Capital's alignment with affordable housing initiatives echoes the ethos of many in the medical profession and could be attractive to others, especially those seeking to yield a positive societal impact through their investments. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 06, 2023 09:00 AM Eastern Standard Time

Bing Ventures Presents Ethereum 2030, Devconnect’s Premier Event

Bing Ventures Limited

Bing Ventures, a Singapore-based pioneering venture capital firm backing early projects in Web3 and Blockchain, is joining hands with leading crypto exchange BingX to present Ethereum 2030: Unraveling Tomorrow’s Innovations, a premier event during Devconnect 2023 on Wednesday, November 15, 2023, at 2:00 pm GMT+3 in Istanbul. Ethereum 2030 will bring together industry heavyweights, visionaries, and trendsetters for a half-day of engaging keynote speeches, in-depth panel discussions, valuable networking opportunities, and audience engagement – all focused on inspiring and nurturing entrepreneurs for a new era of innovation. The event will be held at Sofitel Istanbul Taksim, which sits in the heart of the city, with unique views of Taksim Square and the mesmerizing Bosphorus and has the capacity to welcome up to 1,000 attendees. The agenda covers various topics, including decentralized finance, Ethereum scalability, Web3 security, and the crypto landscape in Turkey. Featured speakers include: Yajin (Andy) Zhou, CEO of Blocksec Azeem Khan, Head of Impact at Gitcoin Jack He, Co-founder at Aspecta Bertuğ Oymak, Co-Founder and CEO of Utilify Dougie DeLuca, Investor at Figment Capital Fatih Taşdemir, Co-Founder of Koin Bülteni Volkan KORKMAZ, CEO and Co-Founder at Altcointurk Luca (Moss) Mossini, BD at Avantgarde & Enzyme Finance Seraphim Czecker, Head of Taking Risk Varuni Trivedi, Editor in Chief at Voice of Crypto Anıl Öz, Chief Technology Officer at DATS Project Arif Kalem, Brand Ambassador of Turkey at BingX Özge ERDEMİR, Web3 Advisor, Business Developer Sima Baktas, Web3 Attorney at GlobalB Law / Co-Founder of CryptoFemale Daria Krasnova, Managing Editor at BeInCrypto Wayne Wu, Partner of Bing Ventures highlighted the purpose of the conference, saying: “As the largest and most established decentralized programmable blockchain in the world, Ethereum has been at the forefront of ground-breaking trends. We’re thrilled to convene a diverse gathering of international and local industry participants to share knowledge, exchange ideas, and inspire one another to push the boundaries of Ethereum.” The event is supported by event partners including Bankless Ventures, Figment Capital, Gitcoin, OneKey, Cedro Finance, Aspecta, Alchemy Pay, CryptoFemale, and Altcointurk, as well as media partners including Cointelegraph, BeinCrypto, Voice of Crypto, Bitcoin Insider, Unlock Blockchain, PANews, Coinpedia, Koinbülteni, and Muhabbit. To learn more and register for the free event, please visit: https://Ethereum2030.eventbrite.sg About Bing Ventures Bing Ventures is a pioneering venture capital firm that backs startups and entrepreneurs driving the next wave of Web3 and blockchain innovations. Its team of crypto veterans and natives collectively brings decades of experience in investing in, incubating, developing, and marketing Web 3.0 projects. With a sector-agnostic, value-investing approach, it now has a portfolio spanning infrastructure, DeFi, GameFi, DAOs, Web3, and more. Contact Details Bing Ventures Jenny Liu +86 159 2140 1005 jenny@bing-ventures.com Company Website https://www.bing-ventures.com/

November 06, 2023 09:00 AM Eastern Standard Time

Image

News Release

Former Analyst at Ark Invest Bullish on Solana - Where Next For Dogecoin and Everlodge?

Total Media

Chris Burniske, a former analyst at Ark Invest, is bullish on the future of Solana (SOL), and investors are diversifying with the cryptocurrency. In addition, Dogecoin (DOGE) and Everlodge (ELDG) are also getting significant attention following their recent price movements. Today, we will jump into the price performance for each crypto to see how far they can spike. Summary Solana is projected to climb in value to $29.22 by the end of 2023 Dogecoin can climb as high as $0.098 by the end of Q4 Everlodge to rise in value by 2,500% at launch Chris Burniske Is Bullish on the Future of Solana (SOL) Solana (SOL) has recently been in the spotlight as it achieved a significant price upswing. With its recent milestone in mind, analysts are bullish on its future. Chris Burniske, a former analyst at Ark Invest, for example, observed how there are several factors that indicate a bullish performance for Solana. The coin's recent price against Ethereum is the foremost indicator. It achieved the 0.02 mark against ETH, which indicates a strong market acceptance and confidence in its future. This breakthrough suggests a potential trajectory towards its next threshold. The Solana trading volume jumped 28% during the past 24 hours. In addition, its value increased from $30.13 to $36.78. In the past two weeks, Solana is up 51.5%. According to the Solana price prediction, it will experience a price upswing to $29.22 by the end of 2023. Dogecoin (DOGE) to See a Rapid Upswing Dogecoin (DOGE) recently saw a price upswing, and analysts are bullish on its future. During the previous week, the price of the Dogecoin crypto moved from $0.065 to $0.074, making $0.080 its next major resistance point. However, the Dogecoin market cap is at $9,799,553,676, and it has remained the 10th largest crypto on the market. According to the current Dogecoin price prediction, it can reach as high as $0.098 by the end of 2023. While this is a bullish outlook, Dogecoin was not the only altcoin to grab attention. Everlodge (ELDG) Can Rise in Value by 2,500% at Launch Everlodge (ELDG) is an upcoming marketplace that will enable anyone to access luxurious properties at a fraction of the cost. In addition, it will eliminate key issues that are plaguing the market. These include high costs of entry, lack of accessibility, and lack of transparency. The properties will get minted as NFTs and, as a result, will enable anyone the opportunity to jump into making investments through the usage of blockchain technology. These NFTs will get split into numerous smaller parts, where investors can begin buying a fraction starting at $100. This means that without needing a lot of upfront capital, anyone can build a diversified portfolio through which they can get passive income, assuming they are rental properties. ELDG can also be staked for passive income, and it is also used for governance. This native token is now at Stage 6 of the presale offered at $0.023. At launch, the crypto can surge as high as 2,500%. For more information about the Everlodge (ELDG) Presale you can visit their website or join their community here. Contact Details Media Team media@everlodge.io

November 03, 2023 11:00 AM Eastern Daylight Time

The AI Image Generator Taking User Creativity to New Frontiers

Hotimage.AI

Artificial intelligence has amazed many with its applications in AI chat, such as ChatGPT. However, AI has also revolutionized the field of image generation. Gone are the days when users needed to spend hours on Photoshop to design a new photo. Now, they can rely on platforms that swiftly bring their ideas to life and transform them into images with the help of an AI image generator. One of the newest AI image generator platforms is hotimage.ai, this site aims to empower users to explore their creativity. It is an easy-to-use and free website where users can delve into their artistic style across various categories, including support for NSFW AI generated images. "The platform's concept is to provide users with a safe environment for crafting images from scratch, without requiring technical expertise, while ensuring that their ideas and fantasies are brought to life with the utmost realism," said Elizabeth Carter, the CEO of hotimage.ai. Key highlights of hotimage.ai include: Realistic Images: The platform creates images that appear real and precise within seconds. Hotimage.ai generates high-quality visual content, suitable for various fields like advertising, entertainment, and product design. Copyright-Free Images: Users can download and utilize images created by the platform without the need for real subjects or models. Speed and Security: The platform can generate lifelike images within seconds while ensuring complete anonymity and security. Versatility: Offering a wide range of options for image generation, hotimage.ai allows users to craft their photos and explore different styles, including animation, artistic renditions, portraits, and AI NSFW content. Using hotimage.ai is simple, just visit the website, choose the desired image category, and begin selecting from the available options. For instance, if you're creating an image featuring a model, you can select various options such as hairstyle, hair color, facial expressions, and background settings. After making your selections, click on "generate," and the platform will swiftly create the desired picture within seconds. Utilizing Artificial Intelligence, AI image generator sites offer a myriad of possibilities in various artistic styles. Users simply provide the details or a general idea, including their "must-haves," and the AI image generator will transform these instructions into a picture within seconds. Contact Details Hotimage.AI support@hotimage.ai Official Website https://hotimage.ai/ Contact Details Adam Scott +1 346-428-8364 support@hotimage.ai

November 03, 2023 10:33 AM Eastern Daylight Time

Image

News Release

Tron Continues Its Uptrend, Bitcoin Cash Is Stagnant, BorroeFinance Investors Are Bullish

Blockchain Digest

Per recent market data, Tron (TRX) is in a sustained rally alongside its Total Value Locked (TVL), which has just obtained a record high. On the flip side, Bitcoin Cash (BCH) continues its protracted passiveness as the bulls struggle to overhaul the bears. Meanwhile, investors remain bullish on the new DeFi project BorroeFinance ($ROE) as it gears up for a parabolic surge. Let’s find out which of these top crypto coins investors may likely delve into. >>BUY $ROE TOKENS NOW<< Tron Surges 9% As TVL Hits All-time High On October 28, market data revealed an impressive development within the Tron (TRX) chain. Accordingly, Tron (TRX) has managed to perform excellently in recent times, setting new records. In particular, the blockchain authorized 6.5 billion transactions, indicating the efficacy and robustness of the Tron (TRX) network. At the same time, Tron’s Total Value Locked (TVL) hit a new milestone of $6.75 billion, accompanied by a 2.23% increase. These impressive demonstrations significantly affected Tron’s native token, TRX. Notably, TRX registered a 9.27% increase between October 16 and October 29. During this period, Tron (TRX) rose from $0.0866 to $0.0948. Due to Tron’s current trajectory, analysts posit that TRX is bound to climb to higher levels. More precisely, they expect to see TRX gain 4.3% to $0.1 in the coming term. Miners Are Dilemmatic Over Bitcoin Cash On-chain activities data showed that Bitcoin Cash (BCH) miners have been on a selling spree over the past month. This selloff resulted in a massive drop in the price of Bitcoin Cash (BCH). On October 24, BCH withdrew from the $265 price range following a period of sharp correction. This pullback represented a 3.85% drop in the price of Bitcoin Cash (BCH). However, as the selloff slowed down, Bitcoin Cash (BCH) witnessed an impulsive bounce. On the weekly timeframe, BCH gained 13.16% on its market value between October 16 and October 22. However, the selling pressure eventually weighed heavily on Bitcoin Cash as BCH only rose 1.11% between October 23 and October 29. This slowdown in activity led experts to assert that Bitcoin Cash (BCH) might maintain this pace in the forthcoming sessions. As a result, they predict that BCH may linger around $242, a 0.1% increase from the current price until significant news or development touching Bitcoin Cash surfaces. BorroeFinance Investors Are Bullish On $ROE BorroeFinance ($ROE) is regarded as one of the best cryptocurrency investment options for both savvy and novice investors. This sentiment is predicated on the capabilities of the platform and the growth map of $ROE. BorroeFinance caters to the needs of buyers and sellers in the Web3 space, making it a pivotal project for people involved in Web3. >>BUY $ROE TOKENS NOW<< BorroeFinance is a marketplace that uses artificial intelligence tools to carry out its services to users. It offers content creators within the Web3 world a platform to trade their future earnings for instant greenbacks. The platform connects buyers and sellers while ensuring that the needs of both parties are duly served. The reason BorroeFinance is considered one of the top DeFi projects in existence is because of its impact on the finance world. BorroeFinance ($ROE) helps businesses and individuals raise funds through an easy and less hectic procedure. The platform is targeted to launch on the Polygon blockchain alongside its native token, $ROE. BorroeFinance is currently in Stage 2 of its public presale, with $ROE trading at $0.015. Investors have the opportunity to benefit from a 167% surge when $ROE hits $0.040 at the end of the presale. Not only that, the token’s value is bound to increase after its official launch on exchanges, creating borderless avenues for investors to earn. Learn more about BorroeFinance ($ROE) here: Visit BorroeFinance Presale | Join The Telegram Group | Follow BorroeFinance on Twitter Contact Details Borroe Finance media@borroefinance.ai

November 03, 2023 10:07 AM Eastern Daylight Time

News Release

Arbitrum Dominates Layer 2 Protocols, BorroeFinance Empowers Web3 Growth Using AI

Blockchain Digest

Arbitrum (ARB) recently recorded another ecosystem win that further cemented its top position among L2 blockchains. While Arbitrum (ARB) built a program that will help developers build better Dapps, BorroeFinance ($ROE) is promoting web3 growth by bridging short-term liquidity gaps in the industry. Let’s see what experts are saying about these two tokens and their predictions for the future. >>BUY $ROE TOKENS NOW<< ARB Surges Amid Positive Ecosystem Development On October 26, Arbitrum (ARB) announced that its long-anticipated Arbitrum Orbit is ‘mainnet-ready.’ The Arbitrum Orbit project will allow blockchain developers to build decentralized apps and new DeFi projects with cutting-edge technology. In addition, developers can create their customized L3 blockchain on any Arbitrum L2 blockchain. The Arbitrum Orbit project has put Arbitrum (ARB) ahead of other L2 blockchains like Optimism and Polygon. Steven Goldfeder, CEO of Offchain Labs, also shared his opinions on the functionalities of Arbitrum Orbit. The CEO said this level of customization and flexibility is a game changer. Arbitrum Orbit will open doors to a new sub-group of L3 blockchain engineers, resulting in an ecosystem expansion. As a result of this positive ecosystem development, ARB gained 9.51% in the last week of October. On October 23, ARB traded at $0.8732. A week later, ARB surged and traded at $0.9591. According to analysts, ARB is at the beginning of its bull rally, and the token could hit $1.5500 in Q1 2024. BorroeFinance: AI Meets Blockchain in New Decentralized Fundraising Platform BorroeFinance ($ROE) is the world’s first web3 blockchain invoice discounting NFT marketplace. This AI-powered fundraising platform allows web3 businesses to generate instant cash by selling future digital earnings. Web3 participants on BorroeFinance ($ROE) can mint their future subscriptions, invoices, and royalties into popular NFTs and sell them to supportive communities at discounted prices. >>BUY $ROE TOKENS NOW<< Supportive communities are active followers on your web3 brand willing to support your business by providing loans to meet immediate short-term liquidity needs. BorroeFinance protects buyer investments by incorporating AI risk assessment, efficient payment solutions, and blockchain technology into its protocol. According to experts, this loan request protocol will guarantee a safe, secure, and straightforward fundraising process. Thankfully, this high-utility project is still in its early stages, and savvy investors are buying the $ROE for $0.015. When $ROE finally hits the mainstream market, the token will surge 167% and trade for $0.040 on major crypto exchanges. If expert predictions play out, $ROE will record fast market adoption and may trade for $0.100 by June 2024. Learn more about BorroeFinance ($ROE) here: Visit BorroeFinance Presale | Join The Telegram Group | Follow BorroeFinance on Twitter Contact Details Borroe Finance media@borroefinance.ai

November 03, 2023 10:05 AM Eastern Daylight Time

Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System

Benzinga

By Jeremy Golden, Benzinga An estimated 609,820 people will die of cancer in the United States this year, according to the National Cancer Institute. Promising results from a 12-year-old clinical-stage biotechnology company have experts optimistic about the future of treating this deadly disease. With its proprietary Amphiphile or “AMP” platform, Elicio Therapeutics Inc. (NASDAQ: ELTX) has developed multiple cancer vaccine candidates that concentrate an array of different immunogens in the lymph nodes. ELI-002 is Elicio’s lead clinical program for Kirsten rat sarcoma (KRAS) driven cancers caused by a mutation of the KRAS gene. An “off the shelf” approach designed to stimulate an immune response against the seven KRAS mutations driving 25% of solid tumors, ELI-002 is currently being studied in AMPLIFY-201 – a phase 1 dose escalation study – and AMPLIFY-7P, a phase 1/2 study. In September, Elicio released new information about the vaccine candidates in its pipeline at the ninth AACR Special Conference on Pancreatic Cancer in Boston. The positive preliminary relapse-free survival (RFS) data from the ongoing AMPLIFY-201 study demonstrated an 86% reduction in risk of progression or death in patients with large T-cell responses induced by ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS. Despite the AMPLIYF-201 study not including a control arm, the median RFS of over 16 months is significantly longer than what has been seen in other studies of similar patient groups. “Patients with mutant KRAS cancers, particularly pancreatic and colorectal cancers, have a poor prognosis with limited treatment options when tumor DNA or protein biomarkers are detected after standard surgery and chemotherapy,” said Eileen M. O’Reilly, M.D., Winthrop Rockefeller Endowed Chair of Medical Oncology and Co-Director of Medical Initiatives at David M. Rubenstein Center for Pancreatic Cancer Research. “We are encouraged by the early data showing ELI-002 induced T cells can positively impact clinical endpoints including the risk of relapse and death in this study.” Targeting Immunogens To Lymph Nodes Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, which are located throughout the body on the lymphatic vessels at various intervals along the lymphatic routes. During the process of circulating throughout the lymphatic system, lymph fluid accumulates antigens and other biomolecules captured from the tissues. This fluid then drains into the lymph nodes, where it encounters T cells and B cells congregating together with antigen-presenting cells (APCs). Targeting the immunogens in the lymph nodes has been proven to result in tumor or pathogen-targeted immunity, including potent T cell and humoral responses, in preclinical trials. Alongside AMPLIFY-201, ELI-002 7P is currently being studied in AMPLIFY-7P, a phase 1/2 trial in patients with high relapse risk mKRAS-driven solid tumors. Designed to provide immune response coverage against seven of the most common KRAS mutations, the ELI-002 7P formulation increases the potential patient population for ELI-002 while possibly reducing the chance of bypassing resistance mechanisms. Moving forward in early 2024, Elicio Therapeutics plans to initiate a randomized phase 2 trial studying ELI-002 7P as a monotherapy in adjuvant PDAC patients. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 03, 2023 09:00 AM Eastern Daylight Time

Preparing for Mexico’s TIIE Transition: Lessons from LIBOR

Tradeweb

The clock is ticking louder on the transition to a new overnight funding rate benchmark for Mexico’s $4.9 trillion swaps market. As we shared in our recent post, Mexico’s TIIE-28 Benchmark is About to Go the Way of LIBOR; Are You Ready?, the Tasa de Interés Interbancaria de Equilibrio, or Interbank Equilibrium Interest Rate (TIIE) will gradually move to a new standard, the TIIE de Fondeo (F-TIIE), starting on January 1, 2024. While many market participants have already begun making the transition and others are busy hammering out their plans, there is still no discernable liquidity benchmarked to the new standard and many questions remain about how, exactly, the marketplace will respond when the switch is flipped next year. Fortunately, we’ve been through this before, and many of the lessons learned over the course of the recent LIBOR migration are also applicable to F-TIIE. Best Practices for a Smooth Transition As a hub of swaps trading activity, Tradeweb played a central role in the transition from LIBOR to the Secured Overnight Financing Rate (SOFR). Now we are working with our clients and Banco de México to share insights and advice on how to navigate the challenges that will inevitably accompany the TIIE transition. We’ve identified several best practices for market participants to prepare for the fast-approaching deadlines, which are January 2024 and January 2025. Collaboration is Key: LIBOR earned its reputation as “the world’s most important number” over the course of a 30-year run, during which it became the interest rate benchmark for hundreds of trillions of dollars of financial instruments globally. Transitioning away from that standard created countless valuation, trade processing and settlement details that needed to be sorted. But it’s important to note that the transition was made possible through close collaboration, including between market participants and regulators who coordinated efforts ahead of target deadlines and communicated frequently. That same spirit of collaboration is already present in the F-TIIE transition, as various stakeholders have been working together to drive a successful outcome. Expect Bumps in the Road: Tradeweb conducted several analyses tracking liquidity in the swaps market throughout the LIBOR transition, monitoring trades benchmarked to LIBOR and those benchmarked to the new SOFR standard over several different time periods. One of our most interesting observations surrounded the July 26, 2021 “SOFR First” phased initiative, where we saw the implied cost of liquidity—as measured by bid-offer spreads—gradually tighten in the weeks and months leading up to the July 26 announcement, then subsequently tighten further. The lesson learned here was that while there was a premium on liquidity using the new benchmark for a short time, but that premium soon faded once the marketplace migrated to the new standard. Benchmark Transitions Happen Gradually, Then All at Once: Another lesson learned in the LIBOR transition was that, although many firms had already done the heavy lifting on preparing themselves to use the new benchmark, the actual adoption was gradual. In fact, the percentage of new U.S. dollar swaps trades benchmarked to SOFR and executed on the Tradeweb platform did not start to trend upward until August of 2021. From there, SOFR adoption grew slowly but steadily until it surged in January 2022 aligned with the regulatory deadline for no new LIBOR origination. The key takeaway here is that even though it may look like many firms have not yet made the conversion, most are in the process of getting ready and will be able to do so when the deadline hits. Electronification Helps: As was the case with LIBOR, the TIIE transition can be made easier for those trading electronically. Obvious benefits like direct integration with order management systems and built-in audit trail for clearing and settlement help to streamline the process. In addition, more advanced capabilities that are only available on electronic markets, such as trade compression tools -- which allow market participants to easily collapse old positions and roll them into a new index in a single transaction -- can ease the process of getting old positions onto the new benchmark. How We’re Helping Fortunately there are plenty of resources and opportunities available to market participants right now to prepare for the transition. One example is Tradeweb’s collaboration with the Banco de México who together in mid-November will convene stakeholders, including clearinghouses, dealers and the investor community to discuss key deadlines, transition strategies and navigating challenges. As we continue to observe and learn best practices from these market participants, we will continue to provide updates here to share what we’ve learned. About Tradeweb Markets Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing and reporting for more than 40 products to clients in the institutional, wholesale and retail markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves more than 2,500 clients in more than 65 countries. On average, Tradeweb facilitated more than $1.2 trillion in notional value traded per day over the past four quarters. For more information, please go to www.tradeweb.com. Forward-Looking Statements This release contains forward-looking statements within the meaning of the federal securities laws. Statements related to, among other things, our outlook and future performance, the industry and markets in which we operate, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions and future events are forward-looking statements. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed under the heading “Risk Factors” in documents of Tradeweb Markets Inc. on file with or furnished to the SEC, may cause our actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements contained in this release are not guarantees of future performance and our actual results of operations, financial condition or liquidity, and the development of the industry and markets in which we operate, may differ materially from the forward-looking statements contained in this release. In addition, even if our results of operations, financial condition or liquidity, and events in the industry and markets in which we operate, are consistent with the forward-looking statements contained in this release, they may not be predictive of results or developments in future periods. Any forward-looking statement that we make in this release speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release. Contact Details Daniel Noonan +1 646-767-4677 Daniel.Noonan@Tradeweb.com Company Website http://www.tradeweb.com

November 02, 2023 05:08 PM Eastern Daylight Time